[go: up one dir, main page]

UA113832C2 - Комбінаційна терапія для хозл - Google Patents

Комбінаційна терапія для хозл

Info

Publication number
UA113832C2
UA113832C2 UAA201207626A UAA201207626A UA113832C2 UA 113832 C2 UA113832 C2 UA 113832C2 UA A201207626 A UAA201207626 A UA A201207626A UA A201207626 A UAA201207626 A UA A201207626A UA 113832 C2 UA113832 C2 UA 113832C2
Authority
UA
Ukraine
Prior art keywords
formoterol
range
copd
composition
relates
Prior art date
Application number
UAA201207626A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA113832(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UA113832C2 publication Critical patent/UA113832C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/009Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65BMACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04Methods of, or means for, filling the material into the containers or receptacles
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65BMACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/003Adding propellants in fluid form to aerosol containers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65BMACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B7/00Closing containers or receptacles after filling
    • B65B7/16Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
    • B65B7/28Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
    • B65B7/2842Securing closures on containers
    • B65B7/285Securing closures on containers by deformation of the closure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Mechanical Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

Винахід належить до аерозольної композиції, придатної для введення ХОЗЛ пацієнтам за допомогою інгалятора зі стисненою виміряною дозою (pMDI), що містить глікопіроній бромід в дозі у діапазоні 0,5-100 мкг на одне приведення у дію у комбінації з формотеролом або його сіллю в дозі у діапазоні 1-25 мкг на одне приведення у дію. Композиція додатково містить HFA пропелент, співрозчинник та кількість неорганічної кислоти - 1М НСІ у діапазоні 0,1-0,3 мкг/мкл, достатньої для стабілізації компонентів як глікопіроній броміду, так і формотеролу. Необов’язково композиція додатково містить беклометазон дипропіонат. Винахід також стосується аерозольного контейнера, способу його наповнення та набору із згаданою композицією.
UAA201207626A 2009-12-23 2010-12-22 Комбінаційна терапія для хозл UA113832C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09180671 2009-12-23
PCT/EP2010/070479 WO2011076843A2 (en) 2009-12-23 2010-12-22 Combination therapy for copd

Publications (1)

Publication Number Publication Date
UA113832C2 true UA113832C2 (xx) 2017-03-27

Family

ID=42107420

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201207626A UA113832C2 (xx) 2009-12-23 2010-12-22 Комбінаційна терапія для хозл

Country Status (40)

Country Link
US (3) US20110150782A1 (uk)
EP (1) EP2515855B3 (uk)
JP (2) JP5914354B2 (uk)
KR (2) KR101757951B1 (uk)
CN (2) CN104055765B (uk)
AR (2) AR079726A1 (uk)
AU (3) AU2010334859A1 (uk)
BR (1) BR112012015337B8 (uk)
CA (1) CA2785321C (uk)
CL (1) CL2012001705A1 (uk)
CO (1) CO6541628A2 (uk)
CY (2) CY1115116T1 (uk)
DK (1) DK2515855T6 (uk)
EA (2) EA027778B1 (uk)
ES (1) ES2468840T7 (uk)
FI (2) FI2515855T6 (uk)
GE (1) GEP20156311B (uk)
HR (1) HRP20140582T4 (uk)
HU (1) HUS1800001I1 (uk)
IL (1) IL260932B (uk)
LT (1) LTC2515855I2 (uk)
LU (1) LUC00060I2 (uk)
MA (1) MA33823B1 (uk)
MX (1) MX2012006878A (uk)
MY (1) MY156949A (uk)
NL (1) NL300923I2 (uk)
NO (1) NO2018001I1 (uk)
NZ (1) NZ600790A (uk)
PE (2) PE20160853A1 (uk)
PH (1) PH12012501066A1 (uk)
PL (1) PL2515855T6 (uk)
PT (1) PT2515855E (uk)
RS (1) RS53391B2 (uk)
SG (1) SG181868A1 (uk)
SI (1) SI2515855T1 (uk)
TN (1) TN2012000269A1 (uk)
TW (1) TWI495468B (uk)
UA (1) UA113832C2 (uk)
WO (1) WO2011076843A2 (uk)
ZA (1) ZA201204615B (uk)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53391B2 (sr) * 2009-12-23 2023-09-29 Chiesi Farm Spa Kombinovana terapija copd-a (hroničnih obstruktivnih bolesti pluća)
WO2011076842A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
CA2785349C (en) * 2009-12-23 2018-07-03 Chiesi Farmaceutici S.P.A. Combination therapy for copd
RU2013142268A (ru) * 2011-02-17 2015-03-27 Сипла Лимитед Фармацевтическая композиция
BR112014008114B1 (pt) * 2011-10-11 2022-07-26 Chiesi Farmaceutici S.P.A. Micropartículas cristalinas, formulação farmacêutica, inalador dosimetrado pressurizado, formulação farmacêutica, processo para preparar microparticulas cristalinas e uso de micropartículas cristalinas
AU2013336492A1 (en) * 2012-10-23 2015-04-09 Cipla Limited Pharmaceutical composition comprising tiotropium and a hydrofluoroalkane
MY176176A (en) 2013-07-11 2020-07-24 Chiesi Farm Spa Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
CN105848642A (zh) * 2013-12-30 2016-08-10 奇斯药制品公司 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物
DK3089735T3 (en) * 2013-12-30 2018-09-17 Chiesi Farm Spa STABLE PRESSURE AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
DK3377108T3 (da) 2015-11-16 2020-04-20 Chiesi Farm Spa Fremgangsmåde til fremstilling af en tørpulverformulering omfattende et anticholinergikum, et corticosteroid og et beta-adrenergikum
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
MA43782A (fr) 2016-03-31 2021-04-28 Chiesi Farm Spa Dispositif d'inhalation d'aérosol
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
MX384545B (es) 2016-09-19 2025-03-14 Mexichem Fluor Sa De Cv Composicion farmaceutica
WO2018051132A1 (en) * 2016-09-19 2018-03-22 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
AU2017328907B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN119656140A (zh) 2017-05-11 2025-03-21 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
RU2742376C1 (ru) * 2017-05-11 2021-02-05 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения состава сухого порошка, содержащего антихолинергическое средство, кортикостероид и бета-адренергетик
MA52756A (fr) * 2018-06-04 2021-04-14 Lupin Inc Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
CA3152578A1 (en) * 2019-12-02 2021-06-10 Enrico Zambelli Stainles steel can for pressurised metered dose inhalers
FI4188327T3 (fi) 2020-07-31 2025-07-25 Chemo Res S L Yhdistelmähoito inhalaatioannosteluun
PE20240629A1 (es) * 2020-10-09 2024-03-26 Chiesi Farm Spa Formulacion farmaceutica para inhalador presurizado de dosis medidas
EP4531922A1 (en) 2022-05-27 2025-04-09 Chiesi Farmaceutici S.p.A. A pharmaceutical formulation for pressurised metered dose inhaler
PE20251253A1 (es) 2022-05-27 2025-05-06 Chiesi Farm Spa Formulacion farmaceutica para inhalador presurizado de dosis medidas
EP4531920A1 (en) 2022-05-27 2025-04-09 Chiesi Farmaceutici S.p.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
EP0673240B1 (en) * 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilized medicinal aerosol solution formulations
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
CN1213732C (zh) * 2000-05-22 2005-08-10 奇斯药制品公司 用于加压计量吸入器的稳定药用溶液制剂
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US20040101483A1 (en) 2001-03-30 2004-05-27 Rudi Muller-Walz Medical aerosol formulations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
AU2003222753B2 (en) 2002-03-01 2008-04-17 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
BR0317340A (pt) 2002-12-16 2005-11-08 Boehringer Ingelheim Pharma Formulações de hfc em solução contendo tiotrópio
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
NZ548302A (en) * 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
WO2005074918A1 (en) 2004-02-06 2005-08-18 Benzstrasse 1 D-61352 Bad Homburd The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1616567A1 (en) 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
GB0505545D0 (en) 2005-03-17 2005-04-27 Glaxo Group Ltd Inhalation devices
MX2007012084A (es) 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
BRPI0614436A2 (pt) 2005-08-01 2011-03-29 Astrazeneca Ab válvula inaladora
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
ES2389231T3 (es) 2005-12-21 2012-10-24 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
AU2008314628B2 (en) 2007-10-18 2014-03-06 Rose U Topical glycopyrrolate formulations
US20110132355A1 (en) * 2009-06-09 2011-06-09 William Gerhart Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
RS53391B2 (sr) * 2009-12-23 2023-09-29 Chiesi Farm Spa Kombinovana terapija copd-a (hroničnih obstruktivnih bolesti pluća)
CA2785349C (en) * 2009-12-23 2018-07-03 Chiesi Farmaceutici S.P.A. Combination therapy for copd
BR112012015335B1 (pt) 2009-12-23 2021-05-18 Chiesi Farmaceutici S.P.A. formulação de aerossol para doença pulmonar obstrutiva crõnica
WO2011076842A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
MY176176A (en) * 2013-07-11 2020-07-24 Chiesi Farm Spa Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
CN105848642A (zh) * 2013-12-30 2016-08-10 奇斯药制品公司 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物
DK3089735T3 (en) * 2013-12-30 2018-09-17 Chiesi Farm Spa STABLE PRESSURE AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
EP2515855B3 (en) 2023-05-03
AR115897A2 (es) 2021-03-10
BR112012015337A2 (pt) 2016-03-15
AU2010334859A1 (en) 2012-07-12
NL300923I2 (en) 2019-07-22
JP6283388B2 (ja) 2018-02-21
RS53391B (sr) 2014-10-31
AU2016234895B2 (en) 2018-02-01
IL260932B (en) 2021-04-29
AU2016234895A1 (en) 2016-10-13
LUC00060I1 (uk) 2018-01-18
US20110150782A1 (en) 2011-06-23
CA2785321A1 (en) 2011-06-30
NO2018001I2 (no) 2018-01-10
US20190046433A1 (en) 2019-02-14
GEP20156311B (en) 2015-07-10
KR101757951B1 (ko) 2017-07-13
LUC00060I2 (uk) 2018-03-16
PL2515855T6 (pl) 2023-12-18
US10159645B2 (en) 2018-12-25
CL2012001705A1 (es) 2012-09-28
US20150328144A1 (en) 2015-11-19
DK2515855T6 (da) 2023-06-06
TWI495468B (zh) 2015-08-11
EA021917B1 (ru) 2015-09-30
CY2017047I2 (el) 2018-04-04
HK1174566A1 (en) 2013-06-14
EA201590179A1 (ru) 2015-09-30
MY156949A (en) 2016-04-15
TW201129359A (en) 2011-09-01
PE20160853A1 (es) 2016-09-14
KR20120103653A (ko) 2012-09-19
WO2011076843A2 (en) 2011-06-30
PL2515855T3 (pl) 2014-08-29
HK1197036A1 (en) 2015-01-02
FIC20170064I1 (fi) 2017-12-29
FI2515855T6 (fi) 2023-06-02
CN102665679B (zh) 2014-11-26
LTC2515855I2 (lt) 2019-05-10
CA2785321C (en) 2018-08-21
ZA201204615B (en) 2013-09-25
US11389401B2 (en) 2022-07-19
CY2017047I1 (el) 2018-04-04
EA027778B1 (ru) 2017-08-31
CY1115116T1 (el) 2016-12-14
DK2515855T3 (da) 2014-06-30
BR112012015337B8 (pt) 2021-05-25
SI2515855T1 (sl) 2014-08-29
SG181868A1 (en) 2012-07-30
EA201290375A1 (ru) 2013-01-30
BR112012015337B1 (pt) 2021-05-04
NZ600790A (en) 2014-09-26
KR20170040392A (ko) 2017-04-12
NL300923I1 (en) 2018-01-17
JP2016145239A (ja) 2016-08-12
CN104055765A (zh) 2014-09-24
MX2012006878A (es) 2012-07-04
JP5914354B2 (ja) 2016-05-11
MA33823B1 (fr) 2012-12-03
EP2515855B1 (en) 2014-04-02
TN2012000269A1 (en) 2013-12-12
EP2515855A2 (en) 2012-10-31
PE20121396A1 (es) 2012-10-24
RS53391B2 (sr) 2023-09-29
ES2468840T3 (es) 2014-06-17
HRP20140582T1 (hr) 2014-08-01
HRP20140582T4 (hr) 2023-06-09
NO2018001I1 (no) 2018-01-10
AU2018202998A1 (en) 2018-05-17
LTPA2018001I1 (lt) 2018-02-12
PT2515855E (pt) 2014-06-11
HUS1800001I1 (hu) 2018-02-28
ES2468840T7 (es) 2023-11-29
CN104055765B (zh) 2016-11-23
CN102665679A (zh) 2012-09-12
WO2011076843A3 (en) 2011-12-01
JP2013515696A (ja) 2013-05-09
PH12012501066A1 (en) 2016-03-02
AR079726A1 (es) 2012-02-15
CO6541628A2 (es) 2012-10-16

Similar Documents

Publication Publication Date Title
UA113832C2 (xx) Комбінаційна терапія для хозл
WO2011076841A3 (en) Combination therapy for copd
MX2013012975A (es) Composiciones farmaceuticas.
AR038641A1 (es) Formulacion superfina de formoterol
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
BR112022014228A2 (pt) Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada
UA106098C2 (uk) Аерозольна композиція для хозл
MX336225B (es) Composiciones que comprenden sulfato de salbutamol.
BRPI0515103A (pt) composição farmacêutica, inalador, processos para preparar o mesmo, e uma composição farmacêutica, e, uso de uma composição farmacêutica
GB0323684D0 (en) Improvements in or relating to organic compounds
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
NZ599900A (en) Pharmaceutical suspension aerosol formulations for use in metered dose inhalers
MX2023003754A (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas.
NZ591174A (en) Metered dose inhaler
JP2004529108A5 (uk)
CL2012000947A1 (es) Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.
WO2004103339A3 (en) Improved metered dose inhaler
TH127043A (th) ผลิตภัณฑ์รวมสำหรับบำบัด copd
BR102012008322B8 (pt) formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa
CR9941A (es) Formacion farmaceutica de absorcion oral y su metodo de administracion